When an asthma drug has an inferiority complex: A noninferiority trial

Pediatrics

Volumn 116, Issue 2, 2005, Pages 493-495

  Goodman, David C ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID DERIVATIVE; FLUTICASONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PLACEBO; STEROID; ACETIC ACID DERIVATIVE; ANDROSTANE DERIVATIVE; ANTIASTHMATIC AGENT; BRONCHODILATING AGENT; QUINOLINE DERIVATIVE;

CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG SUBSTITUTION; FOLLOW UP; FORCED EXPIRATORY VOLUME; FUNCTIONAL DISEASE; HEALTH CARE UTILIZATION; HUMAN; LONG TERM CARE; MILD PERSISTENT ASTHMA; NOTE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; ADOLESCENT; ASTHMA; CHILD; INHALATIONAL DRUG ADMINISTRATION; METHODOLOGY;

ACETATES; ADMINISTRATION, INHALATION; ADOLESCENT; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CHILD; HUMANS; LEUKOTRIENE ANTAGONISTS; QUINOLINES; RESEARCH DESIGN;

EID: 33644627706     PISSN: 00314005     EISSN: 00314005     Source Type: Journal    
DOI: 10.1542/peds.2005-1231     Document Type: Note

References (13)

1. Garcia MLG, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC Study. Pediatrics. 2005;116:360-369
2. Steinijans VW, Neuhauser M, Hummel T, Leichtl S, Rathgeb F, Keller A. Asthma management: the challenge of equivalence. Int J Clin Pharmacol Ther. 1998;36:117-125
3. James Hung HM, Wang SJ, Tsong Y, Lawrence J, O'Neil RT. Some fundamental issues with non-inferiority testing in active controlled trials. Stat Med. 2003;22:213-225
4. D'Agostino RB Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Stat Med. 2003;22:169-186
5. Ducharme F, Di Salvio F. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2005;(2):1-146
6. Maspero JF, Duenas-Meza E, Volovitz B, et al. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy. Curr Med Res Opin. 2001;17:96-104
7. National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma - Update on Selected Topics 2002. Bethesda, MD: National Institutes of Health; 2003. NIH Publication No. 02-5074
8. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA. 1998;279:1181-1186
9. Yaphe J, Edman R, Knishkowy B, Herman J. The association between funding by commercial interests and study outcome in randomized controlled drug trials. Fam Pract. 2001;18:565-568
10. Djulbegovic B, Lacevic M, Cantor A, et al. The uncertainty principle and industry-sponsored research. Lancet. 2000;356:635-638
11. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003;326:1171-1173
12. Bhandari M, Busse JW, Jackowski D, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ. 2004;170:477-480
13. Montgomery JH, Byerly M, Carmody T, et al. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Control Clin Trials. 2004;25:598-612